Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846489 | 0.92 | TYR (0.70) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL4370686 | 0.89 | TYR (0.81) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL30045833 | 0.86 | TYR (0.77) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL8398793 | 0.86 | TYR (0.81) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL8398763 | 0.86 | TYR (0.81) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL8401879 | 0.86 | TYR (0.81) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL8401997 | 0.86 | TYR (0.81) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL950883 | 0.86 | TYR (0.77) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL27903104 | 0.84 | TYR (0.48) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL1397158 | 0.84 | TYR (1.00) | TYRALOX5MEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390343-B1 | RESORCINOL DERIVATIVES FOR COSMETIC USE THEREOF | OREAL (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-10457619-B2 | Resorcinol derivatives for cosmetic use thereof | L'OREAL (FR) | 2019-10-29 | — | — | US | disclosed |
| WO-2017102536-A1 | RESORCINOL DERIVATIVES FOR COSMETIC USE THEREOF | L'OREAL (FR) | 2017-06-22 | — | — | WO | disclosed |
| EP-1430147-B1 | FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS | EPOCH BIOSCIENCES INC (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1235938-B1 | FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS | EPOCH BIOSCIENCES INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7897736-B2 | Fluorescent quenching detecting reagents and methods | ELITECH HOLDING B.V. (NL) | 2011-03-01 | — | — | US | disclosed |
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100174058-A1 | FLUORESCENT QUENCHING DETECTING REAGENTS AND METHODS | ELITECHGROUP, INC. | 2010-07-08 | — | — | US | disclosed |
| US-7662942-B2 | Oligonucleotide probes containing two labels useful in hybridization assays | Elitech Holdings, B.V. (NL) | 2010-02-16 | — | — | US | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
| US-6727356-B1 | AS PROBES SUCH AS FOR FLUORESCENCE RESONANCE ENERGY TRANSFER; QUENCHER INCLUDES A 4-(PHENYLDIAZENYL)PHENYLAMINE STRUCTURE; IMPROVED SIGNAL TO NOISE RATIO AND HYBRIDIZATION | EPOCH PHARMACEUTICALS, INC. | 2004-04-27 | — | — | US | disclosed |
| US-6699975-B2 | OLIGONUCLEOTIDE FOR USE AS TOOL IN THE DETECTION OF PREFERENTIAL COMPOUNDS IN SOLUTION | EPOCH BIOSCIENCES, INC. | 2004-03-02 | — | — | US | disclosed |
| US-6653473-B2 | Nucleotide sequences for use as diagnostic tool in genetic analysis | EPOCH BIOSCIENCES, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030096254-A1 | Enhancing resonance ability of oligonuclotide probes for use in hybridization assays; gene expression | EPOCH BIOSCIENCES, INC. (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030008304-A1 | Fluorescent quenching detection reagents and methods | EPOCH BIOSCIENCES, INC. (US) | 2003-01-09 | — | — | US | disclosed |
| WO-2002099141-A1 | FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS | EPOCH BIOSCIENCES, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-20020155484-A1 | Fluorescent quenching detection reagents and methods | EPOCH PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1235938-A2 | FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS | Epoch Biosciences, Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020034754-A1 | Fluorescent quenching detection reagents and methods | ELITECHGROUP, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2001042505-A2 | FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS | EPOCH BIOSCIENCES, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008304-A1 | Fluorescent quenching detection reagents and methods | DDX5, DDX21, DCLRE1B | TYR 3084/4885ALOX5 2546/4885MEN1 4473/4885 |
| US-20020034754-A1 | Fluorescent quenching detection reagents and methods | DDX5, DDX21, DCLRE1B | TYR 3084/4885ALOX5 2546/4885MEN1 4473/4885 |
| US-20100174058-A1 | FLUORESCENT QUENCHING DETECTING REAGENTS AND METHODS | DDX5, DDX21, DCLRE1B | TYR 2808/4885ALOX5 2506/4885MEN1 4173/4885 |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | TYR 1/4885ALOX5 63/4885MEN1 4836/4885 |
| US-10457619-B2 | Resorcinol derivatives for cosmetic use thereof | CBR3, C1S, TYR | TYR 3/4885ALOX5 135/4885MEN1 2157/4885 |
| US-20020155484-A1 | Fluorescent quenching detection reagents and methods | IPO4, PTBP3, DDX5 | TYR 908/4885ALOX5 2225/4885MEN1 4692/4885 |
| US-20030096254-A1 | Enhancing resonance ability of oligonuclotide probes for use in hybridization assays; gene expression | DCLRE1B, SNRPE, ZFR | TYR 4520/4885ALOX5 4369/4885MEN1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.